Trial Information

Official Title: A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

Summary

The purpose of this study is to evaluate the safety and tolerability of multiple doses of BIIB037 administered via intravenous (IV) infusions in subjects with prodromal or mild Alzheimer's Disease (AD). Patients who meet the inclusion criteria will be eligible for a dose-blinded long-term extension (LTE), following the double-blinded placebo-controlled portion, with all subjects receiving BIIB037.

Phase: Phase 1

Sponsor: Biogen Idec

Overall Contacts:

Medical Director

221AD103@biogenidec.com